JP6894664B2 - 病的な石灰化および骨化を治療するための組成物および方法 - Google Patents

病的な石灰化および骨化を治療するための組成物および方法 Download PDF

Info

Publication number
JP6894664B2
JP6894664B2 JP2015558092A JP2015558092A JP6894664B2 JP 6894664 B2 JP6894664 B2 JP 6894664B2 JP 2015558092 A JP2015558092 A JP 2015558092A JP 2015558092 A JP2015558092 A JP 2015558092A JP 6894664 B2 JP6894664 B2 JP 6894664B2
Authority
JP
Japan
Prior art keywords
npp1
polypeptide
npp4
fragment
activity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2015558092A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016509023A5 (OSRAM
JP2016509023A (ja
Inventor
デメトリオス ブラドック
デメトリオス ブラドック
ロナルド アルブライト
ロナルド アルブライト
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yale University
Original Assignee
Yale University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yale University filed Critical Yale University
Publication of JP2016509023A publication Critical patent/JP2016509023A/ja
Publication of JP2016509023A5 publication Critical patent/JP2016509023A5/ja
Priority to JP2019135862A priority Critical patent/JP6944977B2/ja
Application granted granted Critical
Publication of JP6894664B2 publication Critical patent/JP6894664B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/04—Phosphoric diester hydrolases (3.1.4)
    • C12Y301/04001—Phosphodiesterase I (3.1.4.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y306/00—Hydrolases acting on acid anhydrides (3.6)
    • C12Y306/01—Hydrolases acting on acid anhydrides (3.6) in phosphorus-containing anhydrides (3.6.1)
    • C12Y306/01009—Nucleotide diphosphatase (3.6.1.9), i.e. nucleotide-pyrophosphatase
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
JP2015558092A 2013-02-13 2014-02-12 病的な石灰化および骨化を治療するための組成物および方法 Active JP6894664B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2019135862A JP6944977B2 (ja) 2013-02-13 2019-07-24 病的な石灰化および骨化を治療するための組成物および方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361764297P 2013-02-13 2013-02-13
US61/764,297 2013-02-13
US201361904786P 2013-11-15 2013-11-15
US61/904,786 2013-11-15
PCT/US2014/015945 WO2014126965A2 (en) 2013-02-13 2014-02-12 Compositions and methods for treating pathological calcification and ossification

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019135862A Division JP6944977B2 (ja) 2013-02-13 2019-07-24 病的な石灰化および骨化を治療するための組成物および方法

Publications (3)

Publication Number Publication Date
JP2016509023A JP2016509023A (ja) 2016-03-24
JP2016509023A5 JP2016509023A5 (OSRAM) 2017-02-16
JP6894664B2 true JP6894664B2 (ja) 2021-06-30

Family

ID=51354667

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2015558092A Active JP6894664B2 (ja) 2013-02-13 2014-02-12 病的な石灰化および骨化を治療するための組成物および方法
JP2019135862A Active JP6944977B2 (ja) 2013-02-13 2019-07-24 病的な石灰化および骨化を治療するための組成物および方法
JP2021104071A Active JP7420766B2 (ja) 2013-02-13 2021-06-23 病的な石灰化および骨化を治療するための組成物および方法
JP2024002210A Pending JP2024026704A (ja) 2013-02-13 2024-01-11 病的な石灰化および骨化を治療するための組成物および方法

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2019135862A Active JP6944977B2 (ja) 2013-02-13 2019-07-24 病的な石灰化および骨化を治療するための組成物および方法
JP2021104071A Active JP7420766B2 (ja) 2013-02-13 2021-06-23 病的な石灰化および骨化を治療するための組成物および方法
JP2024002210A Pending JP2024026704A (ja) 2013-02-13 2024-01-11 病的な石灰化および骨化を治療するための組成物および方法

Country Status (6)

Country Link
US (7) US9744219B2 (OSRAM)
EP (2) EP2956163B1 (OSRAM)
JP (4) JP6894664B2 (OSRAM)
ES (1) ES3014398T3 (OSRAM)
PL (1) PL2956163T3 (OSRAM)
WO (1) WO2014126965A2 (OSRAM)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021143202A (ja) * 2013-02-13 2021-09-24 イエール ユニバーシティ 病的な石灰化および骨化を治療するための組成物および方法
US12128087B2 (en) 2015-05-19 2024-10-29 Yale University Compositions for treating pathological calcification conditions, and methods using same
US12134790B2 (en) 2017-09-27 2024-11-05 Inozyme Pharma, Inc. Methods of improving cardiovascular function and treating cardiovascular disease using a recombinant ectonucleotide pyrophosphatase phosphodiesterase (NPP1)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE49529E1 (en) 2014-12-19 2023-05-16 Inozyme Pharma, Inc. Methods of treating tissue calcification
US20180371434A1 (en) * 2015-11-20 2018-12-27 Yale University Compositions for Treating Ectopic Calcification Disorders, and Methods Using Same
EP3471747A1 (en) * 2016-06-16 2019-04-24 Alexion Pharmaceuticals, Inc. Methods of treating myointimal proliferation
AU2017306549A1 (en) * 2016-08-05 2019-02-21 Yale University Compositions and methods for stroke prevention in pediatric sickle cell anemia patients
WO2019217373A1 (en) * 2018-05-08 2019-11-14 Yale University Compositions and methods for reducing progression of nephrolithiasis
CN120383683A (zh) * 2018-08-31 2025-07-29 耶鲁大学 Enpp1多肽及其使用方法
BR112022024958A2 (pt) 2020-06-09 2022-12-27 Inozyme Pharma Inc Proteínas enpp1 solúveis e usos das mesmas
CN116322742A (zh) * 2020-07-02 2023-06-23 依诺兹梅制药公司 用于治疗同种异体移植物血管病、烟雾病、烟雾病综合征和内膜增殖的组合物和方法
WO2022076848A1 (en) * 2020-10-08 2022-04-14 Inozyme Pharma, Inc. Liver specific production of enpp1 or enpp3

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5023243A (en) 1981-10-23 1991-06-11 Molecular Biosystems, Inc. Oligonucleotide therapeutic agent and method of making same
US5190931A (en) 1983-10-20 1993-03-02 The Research Foundation Of State University Of New York Regulation of gene expression by employing translational inhibition of MRNA utilizing interfering complementary MRNA
US5225538A (en) 1989-02-23 1993-07-06 Genentech, Inc. Lymphocyte homing receptor/immunoglobulin fusion proteins
US5168053A (en) 1989-03-24 1992-12-01 Yale University Cleavage of targeted RNA by RNAase P
US6156501A (en) 1993-10-26 2000-12-05 Affymetrix, Inc. Arrays of modified nucleic acid probes and methods of use
US6043056A (en) 1998-11-06 2000-03-28 Incyte Pharmaceuticals, Inc. Cell surface glycoproteins
US20020183276A1 (en) * 2001-03-23 2002-12-05 Burnham Institute Compositions and methods for modulating bone mineral deposition
US7888372B2 (en) 2001-03-23 2011-02-15 National Institutes Of Health (Nih) Compositions and methods for modulating bone mineral deposition
WO2003016475A2 (en) 2001-08-14 2003-02-27 The General Hospital Corporation Nucleic acid and amino acid sequences involved in pain
AU2003213246A1 (en) 2002-02-21 2003-09-09 University Of Virginia Patent Foundation Bone targeting peptides
GB0803352D0 (en) 2008-02-22 2008-04-02 Ntnu Technology Transfer As Oligopeptidic compounds and uses thereof
WO2011113027A2 (en) * 2010-03-12 2011-09-15 Synageva Biopharma Corp Npp1 fusion proteins
KR101772366B1 (ko) 2011-03-11 2017-08-28 알렉시온 파마슈티칼스, 인코포레이티드 Ｎｐｐ１ 융합 단백질
WO2014126965A2 (en) * 2013-02-13 2014-08-21 Yale University Compositions and methods for treating pathological calcification and ossification
USRE49529E1 (en) * 2014-12-19 2023-05-16 Inozyme Pharma, Inc. Methods of treating tissue calcification
EP3298140B1 (en) 2015-05-19 2024-04-24 Yale University Compositions for treating pathological calcification conditions, and methods using same

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021143202A (ja) * 2013-02-13 2021-09-24 イエール ユニバーシティ 病的な石灰化および骨化を治療するための組成物および方法
JP7420766B2 (ja) 2013-02-13 2024-01-23 イエール ユニバーシティ 病的な石灰化および骨化を治療するための組成物および方法
US12128087B2 (en) 2015-05-19 2024-10-29 Yale University Compositions for treating pathological calcification conditions, and methods using same
US12134790B2 (en) 2017-09-27 2024-11-05 Inozyme Pharma, Inc. Methods of improving cardiovascular function and treating cardiovascular disease using a recombinant ectonucleotide pyrophosphatase phosphodiesterase (NPP1)

Also Published As

Publication number Publication date
JP2021143202A (ja) 2021-09-24
US9913881B2 (en) 2018-03-13
US20220152163A1 (en) 2022-05-19
US20150359858A1 (en) 2015-12-17
EP4523757A2 (en) 2025-03-19
JP2024026704A (ja) 2024-02-28
US20170354719A1 (en) 2017-12-14
US20200237882A1 (en) 2020-07-30
JP7420766B2 (ja) 2024-01-23
HK1214952A1 (en) 2016-08-12
EP4523757A3 (en) 2025-07-16
JP2019196392A (ja) 2019-11-14
US20170333533A1 (en) 2017-11-23
WO2014126965A3 (en) 2014-10-09
EP2956163A4 (en) 2017-03-22
EP2956163A2 (en) 2015-12-23
JP6944977B2 (ja) 2021-10-06
US20170252414A1 (en) 2017-09-07
US10624958B2 (en) 2020-04-21
US11266722B2 (en) 2022-03-08
WO2014126965A2 (en) 2014-08-21
EP2956163B1 (en) 2024-11-27
US10052367B2 (en) 2018-08-21
ES3014398T3 (en) 2025-04-22
JP2016509023A (ja) 2016-03-24
US20180318401A1 (en) 2018-11-08
PL2956163T3 (pl) 2025-04-14
US9744219B2 (en) 2017-08-29

Similar Documents

Publication Publication Date Title
JP6944977B2 (ja) 病的な石灰化および骨化を治療するための組成物および方法
JP2024009116A (ja) 病的石灰化状態を治療するための組成物およびそれを使用する方法
WO2003078658A2 (en) Methods for diagnosing and treating schizophrenia
JP2004504063A (ja) 新規線維芽細胞増殖因子（ｆｇｆ２３）および使用方法
JP2022046619A (ja) 異所性石灰化障害を治療するための組成物およびそれを使用する方法
KR20130003071A (ko) Ｅｒｂｂ2 수용체에 선택적으로 결합하는 압타머 및 이의 용도
JP2006508642A (ja) 脂肪の蓄積を減少させる方法と、関連疾患を治療するための方法
WO2005103288A1 (ja) スクリーニング方法
EP3973958A2 (en) Inhibitors of pcsk9 for treatment of lipoprotein metabolism disorders
WO2004053157A2 (en) Methods for diagnosing and treating schizophrenia
JP2004512019A (ja) ホスホジエステラーゼ
US20090298764A1 (en) Gene and pathway and their use in methods and compositions for predicting onset or progression of autoimmune and/or autoinflammatory diseases
HK40123811A (en) Compositions and methods for treating pathological calcification and ossification
JP2006081547A (ja) アトピーにおけるａｎｇｅ遺伝子
WO2003007793A2 (en) Compositions, methods, and kits related to treating and diagnosing hypertension
CA2405078A1 (en) Novel human gene relating to respiratory diseases, obesity, and inflammatory bowel disease
CN115244179A (zh) 用于治疗和预防前激肽释放酶相关疾患的组合物和方法
HK1214952B (en) Compositions for treating pathological calcification and ossification
JP2011514327A (ja) Ｆａｒｐ２およびＳｔｋ２５およびその使用
WO2002033071A1 (fr) Polypeptides analogues a la survivine et leurs adn
WO2003087155A1 (fr) Nouvelle proteine et son adn
JP2003047479A (ja) ビタミンｄ３水酸化酵素
JP2005006644A (ja) 新規タンパク質およびそのｄｎａ
WO2006101273A1 (ja) 癌の予防・治療剤

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170113

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170113

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20171107

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20171207

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180305

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180313

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180718

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20181016

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20190325

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190724

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20190724

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20190724

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20190813

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20190814

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20190920

C211 Notice of termination of reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C211

Effective date: 20190925

C22 Notice of designation (change) of administrative judge

Free format text: JAPANESE INTERMEDIATE CODE: C22

Effective date: 20200601

C22 Notice of designation (change) of administrative judge

Free format text: JAPANESE INTERMEDIATE CODE: C22

Effective date: 20200706

C13 Notice of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: C13

Effective date: 20200824

C28A Non-patent document cited

Free format text: JAPANESE INTERMEDIATE CODE: C2838

Effective date: 20200824

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201124

C141 Inquiry by the administrative judge

Free format text: JAPANESE INTERMEDIATE CODE: C141

Effective date: 20201221

C22 Notice of designation (change) of administrative judge

Free format text: JAPANESE INTERMEDIATE CODE: C22

Effective date: 20201221

C54 Written response to inquiry

Free format text: JAPANESE INTERMEDIATE CODE: C54

Effective date: 20210319

C23 Notice of termination of proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C23

Effective date: 20210412

C03 Trial/appeal decision taken

Free format text: JAPANESE INTERMEDIATE CODE: C03

Effective date: 20210512

C30A Notification sent

Free format text: JAPANESE INTERMEDIATE CODE: C3012

Effective date: 20210512

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20210601

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20210604

R150 Certificate of patent or registration of utility model

Ref document number: 6894664

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250